Kiniksa Pharmaceuticals International (KNSA) Q4 2024 earnings summary

Executive summary

• ARCALYST net product revenue reached $122.5M in Q4 2024 and $417.0M for the full year, up 79% year-over-year.

• 2025 ARCALYST net product revenue is projected at $560–$580M, reflecting continued commercial momentum.

• KPL-387 Phase 2/3 trial in recurrent pericarditis to start mid-2025; Phase 2 data expected in H2 2026 and potential launch by 2028–2029.

• Discontinued abiprubart development in Sjögren's Disease to focus on core cardiovascular portfolio; strategic alternatives to be explored.

• Ended 2024 with $243.6M in cash, cash equivalents, and short-term investments, with no debt.

Financial highlights

• Q4 2024 ARCALYST net product revenue was $122.5M, up from $71.2M in Q4 2023.

• Full year 2024 ARCALYST net revenue was $417.0M, up from $233.2M in 2023.

• Q4 2024 net loss was $8.9M; full year 2024 net loss was $43.2M.

• Operating expenses rose to $141.8M in Q4 2024 and $468.9M for the year, driven by higher collaboration and R&D costs.

• Cash, cash equivalents, and short-term investments totaled $243.6M at year-end, up from $206.4M a year prior.

Outlook and guidance

• 2025 ARCALYST net revenue guidance set at $560–$580M.

• Current operating plan expected to remain cash flow positive on an annual basis.

• KPL-387 Phase 2/3 trial to start mid-2025, with Phase 2 data expected in H2 2026.